Rhopressa, Rhokiinsa(netarsudil)
Rhokiinsa, Rhopressa, Rocklatan, Roclanda (netarsudil) is a small molecule pharmaceutical. Netarsudil was first approved as Rhopressa on 2017-12-18. It is used to treat ocular hypertension and open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. It is known to target rho-associated protein kinase 1 and rho-associated protein kinase 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
eye diseases | D005128 |
Trade Name
FDA
EMA
Rhopressa
CombinationsRocklatan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
ocular hypertension | EFO_1001069 | D009798 | H40.0 |
open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Latanoprost / Netarsudil Dimesylate, Rocklatan, Alcon Labs Inc | |||
9415043 | 2034-03-14 | DP | |
9931336 | 2034-03-14 | DS, DP | U-1524 |
9993470 | 2034-03-14 | DS, DP | U-1524 |
10588901 | 2034-03-14 | DS, DP | U-1524 |
11185538 | 2034-03-14 | DP | |
11197853 | 2034-03-14 | DP | |
8394826 | 2030-11-10 | DS, DP | U-1524 |
10174017 | 2030-01-27 | DS, DP | U-1524 |
10654844 | 2030-01-27 | DS, DP | U-1524 |
11028081 | 2030-01-27 | U-1524 | |
11618748 | 2030-01-27 | U-1524 | |
8450344 | 2026-07-11 | DS, DP | U-1524 |
9096569 | 2026-07-11 | DS, DP | U-1524 |
10532993 | 2026-07-11 | U-1524 | |
10882840 | 2026-07-11 | U-1524 | |
11021456 | 2026-07-11 | U-1524 |
HCPCS
No data
Clinical
Clinical Trials
30 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | 7 | 7 | 1 | 1 | 17 |
Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | 5 | 8 | 1 | 2 | 16 |
Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 1 | 1 | — | 2 |
Low tension glaucoma | D057066 | EFO_1001022 | H40.12 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Fuchs' endothelial dystrophy | D005642 | EFO_0003946 | H18.51 | 2 | 2 | 3 | — | — | 5 |
Proliferative vitreoretinopathy | D018630 | EFO_1001129 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Corneal edema | D015715 | EFO_1000879 | H18.20 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
Cataract | D002386 | EFO_0001059 | H26.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | NETARSUDIL |
INN | netarsudil |
Description | Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The European Medicines Agency approved it in 2019 for the same uses under the brand name Rhokiinsa.
|
Classification | Small molecule |
Drug class | vasodilators (undefined group): Rho protein kinase (ROCK) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1 |
Identifiers
PDB | — |
CAS-ID | 1254032-66-0 |
RxCUI | — |
ChEMBL ID | CHEMBL4594250 |
ChEBI ID | — |
PubChem CID | 66599893 |
DrugBank | DB13931 |
UNII ID | W6I5QDT7QI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ROCK1
ROCK1
ROCK2
ROCK2
Organism
Homo sapiens
Gene name
ROCK1
Gene synonyms
NCBI Gene ID
Protein name
rho-associated protein kinase 1
Protein synonyms
p160 ROCK-1, p160ROCK, Renal carcinoma antigen NY-REN-35, Rho-associated, coiled-coil-containing protein kinase 1, Rho-associated, coiled-coil-containing protein kinase I, ROCK-I
Uniprot ID
Mouse ortholog
Rock1 (19877)
rho-associated protein kinase 1 (Q8C7H0)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 346 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,672 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more